Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company with a mission to innovate and develop small-molecule, molecularly-targeted, oral therapies for the treatment of serious diseases, including liver diseases and cancers. Based in San Mateo, California and Shanghai, Terns leverages its expertise in disease biology and medicinal chemistry to advance its growing pipeline of drugs aimed at addressing significant unmet medical needs globally.
The company is renowned for its cost-efficient drug discovery model and robust clinical development capabilities, especially within China. Terns Pharmaceuticals is focused on developing a portfolio of small-molecule candidates tailored for non-alcoholic steatohepatitis (NASH), oncology, and obesity.
One of the company's flagship programs is the TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist aimed at treating NASH. The Phase 2a DUET clinical trial revealed promising results, showing significant impacts on liver fat content and fibro-inflammation markers within a short period. This positions TERN-501 as a potential leading therapy for NASH.
Additionally, Terns is developing TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a small-molecule GLP-1 receptor agonist for obesity. Both candidates have shown encouraging preclinical and early clinical data, promising significant advancements in their respective fields.
Financially, as of the latest quarter, Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, supporting the planned operating expenses into 2026. Recent clinical trials and corporate updates highlight the company's ongoing dedication to addressing global health challenges through innovative drug development.
For more information, please visit their website at www.ternspharma.com.
Terns Pharmaceuticals presented positive Phase 1 results for TERN-501, a THR-β agonist targeting NASH, at The Liver Meeting. Among 24 participants, TERN-501 demonstrated a dose-dependent increase in sex hormone binding globulin (SHBG), with 100% of those on the highest dose showing significant increases. The ongoing Phase 2a DUET trial will evaluate TERN-501's safety and efficacy, both alone and in combination with TERN-101, with top-line data expected in late 2023.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced plans to present two abstracts at the AASLD The Liver Meeting® from November 4-8, 2022. The presentations will focus on TERN-501, a THR-β agonist, and TERN-101, an FXR agonist, both under investigation for treating non-alcoholic steatohepatitis (NASH). The first abstract highlights TERN-501’s effects on sex hormone binding globulin and lipid levels, while the second discusses an ongoing Phase 2a study of TERN-501 and TERN-101 in NASH patients, with top-line results expected in late 2023.
Terns Pharmaceuticals, based in Foster City, is set to present at the H. C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, at 11:30 a.m. ET. The company focuses on developing small-molecule therapies targeting serious diseases, including oncology, obesity, and non-alcoholic steatohepatitis (NASH). A live webcast of the presentation will be available on their investor relations page, with a replay accessible for 30 days. Terns' pipeline includes multiple clinical-stage programs aimed at serious health conditions.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company (Nasdaq: TERN), is set to present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 2:00 p.m. ET. The company focuses on developing small-molecule therapies for serious diseases, including oncology, obesity, and non-alcoholic steatohepatitis (NASH). Interested investors can access a live audio webcast of the presentation on Terns' investor relations page, with a replay available for 30 days post-event.
Terns Pharmaceuticals has announced an underwritten public offering of 12,250,000 shares at $2.42 each and pre-funded warrants for 14,630,000 additional shares at $2.4199 each, targeting gross proceeds of approximately $65 million. The offering, which is set to close on August 16, 2022, is oversubscribed and led by new investors, including Fairmount and Venrock Healthcare Capital Partners. Proceeds will fund clinical studies in chronic myeloid leukemia, obesity, and ongoing trials for NASH, alongside general corporate purposes.
Terns Pharmaceuticals reported progress on its clinical trials for three drug candidates targeting chronic myeloid leukemia, obesity, and NASH. TERN-701 is advancing to a Phase 1 trial in China, while TERN-601 is on schedule to begin a Phase 1 obesity trial in 2023. The company initiated dosing for TERN-501 in a Phase 2a trial for NASH, with results expected in the second half of 2023. As of June 30, 2022, Terns has $140 million in cash, providing a financial runway into 2025, despite a net loss of $13.9 million for the quarter.
On July 27, 2022, Terns Pharmaceuticals (Nasdaq: TERN) appointed Dr. Radhika Tripuraneni to its Board of Directors. Dr. Tripuraneni, the Chief Development Officer at Prothena Corporation, boasts over 15 years of drug development experience. She aims to leverage her expertise to guide Terns in advancing its pipeline of small-molecule candidates targeting serious diseases such as NASH, obesity, and cancer. CEO Sen Sundaram emphasized her valuable support in generating meaningful clinical data for these significant unmet needs.
Terns Pharmaceuticals presented positive results from its Phase 1 trial of TERN-501 at the EASL International Liver Congress 2022. The treatment was well-tolerated and showed significant dose-dependent effects on key biomarkers after 14 days. The company also highlighted its pipeline, including TERN-101 and TERN-201, with promising data supporting their potential in treating non-alcoholic steatohepatitis (NASH). Terns announced they will initiate a combination NASH trial with TERN-501 and TERN-101, with results expected in late 2023.
On June 8, 2022, Terns Pharmaceuticals (Nasdaq: TERN) announced that five abstracts concerning its non-alcoholic steatohepatitis (NASH) programs have been accepted for presentation at The International Liver Congress 2022, scheduled for June 22-26 in London. Key presentations include results from a first-in-human trial of TERN-501 and safety data on TERN-101 and TERN-201, showcasing their potential efficacy and favorable safety profiles. All abstracts will be published in the Journal of Hepatology.
Terns Pharmaceuticals has appointed Kerry Russell, M.D., Ph.D., as its new chief medical officer, reporting to Erin Quirk, M.D., President and Head of Research & Development. This strategic move aims to enhance Terns' expertise, particularly in progressing its clinical pipeline targeting serious diseases like non-alcoholic steatohepatitis (NASH), obesity, and chronic myeloid leukemia. With several key clinical trial data readouts expected in the coming years, Terns is focused on advancing its promising pipeline candidates.
FAQ
What is the current stock price of Terns Pharmaceuticals (TERN)?
What is the market cap of Terns Pharmaceuticals (TERN)?
What does Terns Pharmaceuticals, Inc. specialize in?
Where is Terns Pharmaceuticals located?
What is TERN-501 and what disease does it target?
What are the main therapeutic areas Terns Pharmaceuticals focuses on?
What is the significance of TERN-701?
How is Terns Pharmaceuticals funded for its operations?
What recent achievement has Terns Pharmaceuticals made in clinical trials?
What is TERN-601 being developed for?
What is the main objective of Terns Pharmaceuticals?
Where can I find more information about Terns Pharmaceuticals' research and development activities?
